Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point‐mutant β‐catenin
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Hepatocellular cancer (HCC) remains a significant therapeutic challenge due to its poorly understood molecular basis. In the current study, we investigated two independent cohorts of 249 and 194 HCC cases for any combinatorial molecular aberrations. Specifically we assessed for simultaneous HMET expression or hMet activation and catenin β1 gene (CTNNB1) mutations to address any concomitant Met and Wnt signaling. To investigate cooperation in tumorigenesis, we coexpressed hMet and β‐catenin point mutants (S33Y or S45Y) in hepatocytes using sleeping beauty transposon/transposase and hydrodynamic tail vein injection and characterized tumors for growth, signaling, gene signatures, and similarity to human HCC. Missense mutations in exon 3 of CTNNB1 were identified in subsets of HCC patients. Irrespective of amino acid affected, all exon 3 mutations induced similar changes in gene expression. Concomitant HMET overexpression or hMet activation and CTNNB1 mutations were evident in 9%‐12.5% of HCCs. Coexpression of hMet and mutant‐β‐catenin led to notable HCC in mice. Tumors showed active Wnt and hMet signaling with evidence of glutamine synthetase and cyclin D1 positivity and mitogen‐activated protein kinase/extracellular signal‐regulated kinase, AKT/Ras/mammalian target of rapamycin activation. Introduction of dominant‐negative T‐cell factor 4 prevented tumorigenesis. The gene expression of mouse tumors in hMet‐mutant β‐catenin showed high correlation, with subsets of human HCC displaying concomitant hMet activation signature and CTNNB1 mutations. Conclusion: We have identified cooperation of hMet and β‐catenin activation in a subset of HCC patients and modeled this human disease in mice with a significant transcriptomic intersection; this model will provide novel insight into the biology of this tumor and allow us to evaluate novel therapies as a step toward precision medicine. (H epatology 2016;64:1587‐1605)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803
Self-citationConditional Deletion of β-Catenin Reveals Its Role in Liver Growth and Regeneration
Tan, X., Behari, J., Cieply, B., Michalopoulos, G. K., & Monga, S. P. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.042 · Cited by 361
Self-citationZucman-Rossi, J., Benhamouche, S., Godard, C., Boyault, S., Grimber, G., Balabaud, C., Cunha, A. S., Bioulac-Sage, P., & Perret, C. (2007) · Oncogene · doi:10.1038/sj.onc.1209824 · Cited by 256
Self-citation
Cited by
Wnt–β-catenin signalling in liver development, health and disease
Perugorria, M. J., Olaizola, P., Labiano, I., Esparza-Baquer, A., Marzioni, M., Marin, J. J. G., Bujanda, L., & Banales, J. M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0075-9 · Cited by 605
Wnt/β-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology
Russell, J. O., & Monga, S. P. (2018) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-044010 · Cited by 471
Self-citationWnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
“The activation of Wnt/β-catenin alone is insufficient to drive hepatocarcinogenesis; instead, its interactions with c-Met, K-RasV12, activated Akt, LKB1, and Nrf2 are necessary for HCC formation in mice. c-Met c-Met has been observed in 10% of human HCC tissue samples [220–224].”
BackgroundWNT/β-catenin signaling in the development of liver cancers
He, S., & Tang, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110851 · Cited by 351
Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis
Filliol, A., Saito, Y., Nair, A., Dapito, D. H., Yu, L.-X., Ravichandra, A., Bhattacharjee, S., Affo, S., Fujiwara, N., Su, H., et al. (2022) · Nature · doi:10.1038/s41586-022-05289-6 · Cited by 349
Self-citation
Metadata
- Authors
- Tao, J., Xu, E., Zhao, Y., Singh, S., Li, X., Couchy, G., Chen, X., Zucman‐Rossi, J., Chikina, M., & Monga, S. P. S.
- Venue
- Hepatology
- Published
- 2016-05-28
- Volume
- 64
- Issue
- 5
- Pages
- 1587-1605
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2462145367
- Cited by
- 125
- References
- 4
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.